Ehlers-Danlos Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Ehlers-Danlos syndrome is a group of connective tissue disorders that are characterized by unstable, hypermobile joints, loose, “stretchy” skin, and tissue fragility. It is caused by a defect in the connective tissue. The fragile tissues, stretchy skin, and unstable joints found in Ehlers-Danlos syndrome are due to a gene mutation in collagen. Vascular Ehlers-Danlos syndrome is an autosomal dominant condition; that is, a child only has to inherit a defect in the COL3A1 gene from one parent to have the disorder. About half of people with vascular Ehlers-Danlos syndrome inherited the COL3A1 mutation from an affected parent. The other half of people with the condition have a spontaneous disease-causing mutation; that is, they are the first person in their family to have vascular Ehlers-Danlos syndrome. Each child of an affected parent has a 50 percent chance of inheriting the mutation and developing the disorder.
·
The estimated prevalence of Ehlers-Danlos
syndrome is 1 in every 5,000 birth.
Thelansis’s
“Ehlers-Danlos Syndrome Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Ehlers-Danlos
Syndrome treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights of Ehlers-Danlos
Syndrome across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Ehlers-Danlos
Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based
Automated Dashboard), which Data Inputs with sourcing, Market Event, and
Product Event, Country specific Forecast Model, Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing
scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Ehlers-Danlos
Syndrome, Ehlers-Danlos Syndrome market outlook, Ehlers-Danlos
Syndrome competitive landscape, Ehlers-Danlos
Syndrome market forecast, Thelansis, Primary market
research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment